ArticleJournal of cellular biochemistry2011
Y-box protein-1 is a transcriptional regulator of BMP7.
Article in Journal of cellular biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- rSjp40 inhibits activated hepatic stellate cells by promoting nuclear translocation of YB1 and inducing BMP-7/Smad1/5/8 pathway.Parasites & vectors · 2019Article
- A multifunctional protein, EWS, is essential for early brown fat lineage determination.Developmental cell · 2013Article
- Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice.The Journal of biological chemistry · 2012Article
- Changes in the expression of bone morphogenetic protein 7 and tamm- horsfall protein in the early stages of diabetic nephropathy.Nephro-urology monthly · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bone morphogenetic protein-7 (BMP7) is an endogenous antifibrogenic protein in the kidney which is down regulated in experimental chronic kidney diseases such as obstructive and diabetic nephropathy in parallel with progressively increasing TGFβ. In vitro studies were performed in Madin-Darby Canine Kidney (MDCK)-cells to identify transcriptional regulators of BMP7. Experiments with various BMP7 promoter fragments (465-4,267 bp) identify small proximal promoter segments that are transcriptionally activated by high glucose (3.2-fold) but down regulated by TGFβ (0.2-fold) compared to normal glucose. Protein binding to these DNA segments is increased by high glucose and decreased by TGFβ in a time-dependent, progressive manner. Analysis of BMP7 promoter-binding proteins with liquid chromatography/tandem mass spectrometry (LC/MS/MS) identifies seven unique, partially overlapping peptides, spanning 25% of the amino acid sequence of Y-box protein-1 (YB1). EMSA-Western blot combination experiments confirm that YB1 is a BMP7 promoter-binding protein. YB1 knock-down reduces transcriptional responses to high glucose and TGFβ by about one-half, respectively. In addition, high glucose induces but TGFβ reduces nuclear translocation of YB1 from the cytoplasm. These studies identify YB1 as a transcriptional activator of BMP7 and helps to explain the progressive decline in renal BMP7 in diabetic nephropathy and other kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.